Candida auris in a tertiary healthcare setting in south India: A case series

Document Type : Original Articles

Authors

1 Department of Microbiology, Nitte (Deemed to be University), KS Hegde Medical Academy (KSHEMA), Deralakatte, Mangalore, Karnataka, India

2 Intern, B.Sc. in Medical Laboratory Technology, Nitte (Deemed to be University), KS Hegde Medical Academy (KSHEMA), Deralakatte, Mangalore, Karnataka, India

Abstract

Candida species can produce a variety of clinical manifestations, and several non-albicans species of Candida, including Candida auris, have been linked to the rise of invasive fungal infections with high rates of treatment failure. Nosocomial outbreaks and high mortality rates in healthcare institutions across the globe have been associated with C. auris, an emerging infectious yeast that was initially discovered in the ear canal of an elderly Japanese patient in 2009. The fact that C. auris has been found on six continents after it was initially isolated has raised serious concerns among scientists and healthcare practitioners.  At present, healthcare facilities lack defined protocols for the effective prevention and control of C. auris infections, as well as appropriate treatment alternatives. This leads to frequent therapeutic failures and complicates the eradication of C. auris infection in healthcare facilities. Studies on C. auris in South India are often limited, and healthcare workers urgently need to be made aware of infections caused by it in order to assess its impact and possible implications for the healthcare system. This study aimed to report seven patients hospitalized in our center who developed C. auris infections with varying clinical manifestations. 
 
 

Keywords

Main Subjects


  1. Kullberg BJ, Arendrup MC. Invasive candidiasis. N Engl J Med.2015; 373:1445–56.
  2. Cortegiani A, Misseri G, Fasciana T, Giammanco A, Giarratano A, Chowdhary A. Epidemiology, clinical characteristics, resistance, and treatment of infections by Candida auris. J Intensive Care. 2018;6:69.
  3. Fan S, Zhan P, Bing J, Jiang N, Huang Y, Chen D, et al. A biological and genomic comparison of a drug-resistant and a drug-susceptible strain of Candida auris isolated from Beijing, China.Virulence. 2021;12:1388–99. 
  4. Garcia-Bustos V, Cabanero-Navalon MD, Ruiz-Saurí A, Ruiz-Gaitán AC, Salavert M, Tormo MÁ, et al. What do we know about Candida auris? State of the art, knowledge, gaps, and future directions. Microorganisms. 2021; 9(10):2177. 
  5. New Delhi, India: ICMR; 2017. Indian Council of Medical Research (ICMR). Candida auris in Healthcare Settings – India.2020.
  6. Centre for Diseases Control and Prevention. Candidiasis.2024.
  7. Gaitán AC, Moret A, López Hontangas JL, et al. Nosocomial fungemia by Candida auris: first four reported cases in continental Europe. Rev Iberoam Micol. 2017; 34(1):23–7.
  8. Izquierdo G, Santolaya ME. Candidiasis invasoras en recién nacidos: diagnóstico, tratamiento y prevención [Invasive candidiasis in newborns: diagnosis, treatment and prophylaxis]. Rev Chilena Infectol. 2014;31(1):73-83.
  9. Santolaya ME, Alvarado Matute T, de Queiroz Telles F et al. Recommendations for the management of candidemia in neonates in latin america. latin america invasive mycosis network. Rev Iberoam Micol. 2013:158-70.
  10. de Araujo Motta F, Dalla-Costa LM, Dominguez Muro M, Lenzi A, Picharski GL, Burger M. Risk Adjustment for Congenital Heart Surgery Score as a Risk Factor for Candidemia in Children Undergoing Congenital Heart Defect Surgery. Pediatr Infect Dis J. 2016;35(11):1194-98.
  11. Mathur, P., F. Hasan, P. Singh, R. Malhotra, K. Walia, and A. Chowdhary. Five-year profile of candidemia at an Indian Trauma Center: high rates of Candida auris blood stream infections. Mycoses. 2018; 61(9):674–80.
  12. Chowdhary A, Prakash A, Sharma C, Kordalewska M, Kumar A, Sarma S, et al. A multicentre study of antifungal susceptibility patterns among 350 Candida auris isolates (2009-17) in India: role of the ERG11 and FKS1 genes in azole and echinocandin resistance. J Antimicrob Chemother. 2018;73(4):891-99.
  13. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdhary A. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrixassisted laser desorption ionization–time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol. 2015; 53:1823–30.
  14. Escandón P, Cáceres DH, Espinosa-Bode A, Rivera S, Armstrong P, Vallabhaneni S, et al. Notes from the Field: Surveillance for Candida auris - Colombia, September 2016-May 2017. MMWR Morb Mortal Wkly Rep. 2018;67(15):459-60.
  15. Alvarado-Socarras JL, Vargas-Soler JA, Franco-Paredes C, Villegas-Lamus KC, Rojas-Torres JP, Rodriguez-Morales AJ. A Cluster of Neonatal Infections Caused by Candida auris at a Large Referral Center in Colombia. J Pediatric Infect Dis Soc. 2021;10(5):549-55.
  16. Organización Panamericana de la Salud/Organización Mundial de la Salud.Alerta Epidemiológica: Brotes de Candida auris en servicios de atención de salud.2016.
  17. Calvo B, Melo AS, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL. First report of Candida auris in America: Clinical and microbiological aspects of 18 episodes of candidemia. J Infect. 2016; 73(4):369-74.

 

 

Volume 9, Issue 4
December 2023
Pages 33-38
  • Receive Date: 23 January 2024
  • Revise Date: 17 March 2024
  • Accept Date: 19 March 2024
  • First Publish Date: 19 March 2024
  • Publish Date: 01 December 2024